title: Role of the renin-angiotensin system in the nandrolone-decanoate-induced attenuation of the Bezold-Jarisch reflex.
abstract: The androgen nandrolone decanoate (ND) is known to cause cardiovascular abnormalities, such as attenuation of the Bezold-Jarisch Reflex (BJR), cardiac hypertrophy, and elevation of mean arterial pressure (MAP). Futhermore, a relationship between androgens and the renin-angiotensin system (RAS) has been reported. The purpose of this study was to evaluate the influence of RAS on the BJR, cardiac and prostatic hypertrophy, and MAP evoked by ND. For this, male Wistar rats were treated with ND (10 mg·(kg body mass)(-1) for 8 weeks; DECA), or vehicle (control animals; CON), or enalapril (10 mg·(kg body mass)(-1), daily; CONE), or ND and enalapril (10 mg ND + 10 mg enalapril per kilogram of body mass; DECAE). After 8 weeks of treatment, the BJR was evaluated by bradycardia and hypotensive responses that were elicited by serotonin administration (2-32 µg·(kg body mass)(-1)). MAP was assessed; cardiac and prostate hypertrophy were determined by the ratio of the tissue mass:body mass, and by histological analysis of the heart. Animals from the DECA group showed prostatic and cardiac hypertrophy, elevation in mean arterial pressure, and an impairment of BJR. Co-treatment with enalapril inhibited these changes. The data from the present study suggest that RAS has an impact on BJR attenuation, cardiac and prostatic hypertrophy, and the elevation in MAP evoked by ND.
authors: Tadeu Uggere
authors: TU
authors: Andrade
authors: a Department of Pharmacy, University Center of Vila Velha, Espírito Santo, Brazil.
authors: Tadeu
authors: T
authors: Uggere de Andrade
authors: Leonardo Zanoteli
authors: LZ
authors: Loiola
authors: Samira Merces Nascimento
authors: SM
authors: Alcure
authors: Ana Raquel Santos
authors: AR
authors: Medeiros
authors: Maria Carmen Lopes Ferreira Silva
authors: MC
authors: Santos
authors: Margareth Ribeiro
authors: MR
authors: Moysés
authors: Gláucia Rodrigues de
authors: GR
authors: Abreu
authors: Dominik
authors: D
authors: Lenz
authors: Nazaré Souza
authors: NS
authors: Bissoli
mesh_terms: D045930:Anabolic Agents / Q000009:adverse effects*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects; D001919:Bradycardia / Q000139:chemically induced / Q000503:physiopathology; D006332:Cardiomegaly / Q000139:chemically induced / Q000503:physiopathology; D004656:Enalapril / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects*; D008297:Male; D009277:Nandrolone / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077603:Nandrolone Decanoate; D011470:Prostatic Hyperplasia / Q000139:chemically induced / Q000503:physiopathology; D017208:Rats, Wistar; D012084:Renin-Angiotensin System / Q000187:drug effects*
chemical_list: D045930:Anabolic Agents; D000806:Angiotensin-Converting Enzyme Inhibitors; D004656:Enalapril; D009277:Nandrolone; D000077603:Nandrolone Decanoate